to the top

1st half figures due next week, recent news from company shows their intentions as to taking company forward. Be dissapointed if figures next week do not show continuing profits as per expectations at least

Stable - I'm sure you are aware , I posted this on the SUN thread yesterday.

RNS Number : 3798N

Advanced Medical Solutions Grp PLC

01 September 2011

For immediate release: 1 September 2011

Advanced Medical Solutions Group plc

("AMS" or the "Company")

Development and Pre-Supply Agreement signed with Surgical Innovations Group plc

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, today announces that it has signed a Development and Pre-Supply Agreement ("the Agreement") with Surgical Innovations Group plc ("Surgical Innovations") (AIM: SUN), for the development and supply of a novel device for internal application of adhesives and sealants.

Under the terms of the Agreement, Surgical Innovations will develop and retain the intellectual property rights for a unique applicator to deliver accurately, individual drops of adhesive or sealant internally within the body, accessed via a minimally invasive surgical port site. In return for the exclusive rights to this applicator for the internal application of adhesives and sealants, AMS has agreed to purchase all of its requirements for the approved new applicator from Surgical Innovations for a period of ten years.

The development of the internal applicator is a key step in extending the Company's expertise in adhesives and sealants from purely topical applications to also addressing clinical needs inside the body. AMS has previously highlighted that the first target internal application would be the hernia mesh fixation market which is currently served by sutures, staples and tacks. This new internal applicator, together with the Company's adhesives, will allow AMS to address this important market with reduced surgical complications.

Commenting on this announcement, Chris Meredith, Chief Executive Officer of AMS said:

"This agreement combines our formulation and regulatory expertise with Surgical Innovations' applicator design and manufacturing expertise to introduce a new product to a global market for internal sealants that is now in excess of US$600 million. As we have previously indicated, an integral part of our tissue sealant and adhesives R&D is focused on moving our product range more towards the Operating Room, including internal applications. In this regard, we are optimistic that our partnership with Surgical Innovations will give us a market leading product, targeting the hernia mesh fixation market, which should be available for launch in 2013."

Graham Bowland, Chief Executive Office of Surgical Innovations added:

"Our agreement with AMS affirms SI's reputation in delivering leading design solutions to OEM customers. The applicator device for AMS is a natural extension to our existing minimally invasive surgical product portfolio and we have already commenced on the design work on a fully disposable device. As part of the agreement SI will retain the full intellectual property rights to the applicator device and will also manufacture it on behalf of AMS."

skinny
Thks, I had already seen it. I think this continues to show that Ams have the mind set to develop the company as it surely leads in time for a take over.

Half Yearly Report.

Business Highlights:

LiquiBand achieves 5% volume share in the US in only its second year of sales

Sales of ActivHeal into the NHS up 64% compared to the same period last year

Foam strategy delivering strong growth of 25% on the first half of 2010

Silver alginate growth continues to outstrip the wider market

New facility already delivering operational efficiencies and margin improvements

Financial Highlights:

Group revenue up 12% to 16.3 million (2010 H1: 14.5 million)

at constant currency1 revenue increased 14%

Profit from operations (pre-exceptional items2) up 25% to 2.6 million (2010 H1: 2.1 million)

profit from operations (post exceptional items2) up 80% to 2.6 million (2010 H1: 1.5 million)

Operating margin (pre-exceptional items2) up 160 basis points to 16.1% (2010 H1: 14.5%)

operating margin (post-exceptional items2) up 610 basis points to 16.1% (2010 H1: 10.0%)
Basic earnings per share (pre-exceptional items2) up 21% to 1.72p (2010 H1: 1.42p)

basic earnings per share (post exceptional items2) up 74% to 1.72p (2010 H1: 0.99p)

Net funds3 after payment of maiden dividend were 3.6 million (2010 H1: net debt 0.3 million)

Interim dividend of 0.145p per share to be paid

RNS Number : 2417T

Advanced Medical Solutions Grp PLC

02 December 2011

THIS ANNOUNCEMENT (INCLUDING THE APPENDIX AND THE INFORMATION CONTAINED HEREIN) IS restricted and is NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL

Strictly Embargoed until 07.00 2 December 2011

Advanced Medical Solutions Group plc ("AMS", the "Company" or the "Group")

Placing of 47,236,112 new Ordinary Shares in AMS at a price of 72 pence per share to raise approximately GBP34.0 million in connection with the proposed acquisition of RESORBA Wundversorgung GmbH & co. KG

The Board of AMS (AIM: AMS), the global medical technology company, is pleased to announce today the proposed acquisition of RESORBA, a long established wound care and wound closure business headquartered in Germany for a total cash consideration of EUR63.8 million (approximately GBP55 million) on a debt-free, cash-free basis to be paid, in full, on completion. To fund the acquisition, the Board of AMS also announces today a non pre-emptive institutional placing (the "Placing") of 47,236,112 new Ordinary Shares in AMS (the "Placing Shares") at a price of 72 pence per Placing Share (the "Placing Price"), to raise approximately GBP34.0 million (GBP30.5 million net of acquisition and placing expenses), together with a EUR25.0 million term loan facility.


-- The acquisition of RESORBA fulfils all of AMS's strategic
acquisition criteria and provides a number of commercial
synergy opportunities as it:
-- Broadens the Group's technology portfolio in both wound
care and wound closure;
-- Provides direct sales capability into the operating
room in Germany, Czech Republic and Russia;
-- Provides significant cross-selling opportunities and
product development potential;
-- Provides access to a new market - oral surgery;
-- Leverages AMS's global distribution network and regulatory
expertise to bring existing RESORBA products to new
markets; and
-- Provides development opportunities in the short, medium
and long term
-- RESORBA is well known to AMS as it currently distributes
its LiquiBand(R) wound closure product and has done for
more than eight years
-- Acquisition is expected to be earnings per share enhancing
in the twelve months ending 31 December 2012(1)
-- Senior management of RESORBA will be joining the Enlarged
Group and investing a material proportion of their net
proceeds from the Acquisition in AMS shares
-- Significant shareholder support for the Placing

(1) This statement is not intended, nor is to be construed as a profit forecast or to be interpreted to mean that earnings per AMS Share for the current or future financial years, or those of the Enlarged Group, will necessarily match or exceed the historical earnings per AMS Share.

Commenting on the Acquisition, Chris Meredith, Chief Executive Officer of AMS said:

"Part of our core growth strategy has been to examine potential acquisition opportunities that strengthen our business with complementary technologies and greater market access, specifically in relation to the operating room segment of our global business. It is rare to find a business that fits our criteria as well as RESORBA does. We have known RESORBA for a number of years as a result of our LiquiBand(R) relationship, and I am confident that the enlarged AMS Group will benefit from a wide range of commercial opportunities that will enable us to continue the strong progress made in recent years."

The Placing is conditional, inter alia, on Shareholder approval of the Special Resolution at the General Meeting. It is expected that the Company will post a Circular to all AMS Shareholders today with details of the Placing, Acquisition, the New Debt Facility and giving notice of the General Meeting, to be held at 11.00 a.m. on 19 December 2011 at the offices of Investec Bank plc, 2 Gresham Street, London EC2V 7QP. A copy of this Announcement and the Circular will be available on the Company's website, www.admedsol.com.

A bit more volume would be nice.

skinny
I think anything over 1 mill is big for ams, recent vloume on downside was one reason for not getting worried as it was very low.
It will be interesting in the middle of this month if they give an update prior to end of year, where will end 2011?

Yes I guess that comparatively speaking, the volume is well above average - I can't lay my hands on it atm, but I've had a sell note on this in the last week - more excellent coverage! :-)

Skinny
re yesterdays trading, I wonder what was the reason for the afternoon volume, either good lunches in london, or was it U.S. buying interest.I do not want a takeover in the near future as I feel all is in place for another 100 pc rise within 24 months, but, I cannot believe a large US company is not watching and knowing the short sighted Uk financial wonders they will take a nice profit if forthcoming,

re your sale note, I saw one about 10 days ago that forecast value at70p and then share magasine talked also about 70p, I wonder what they are saying this week

Now there's a bit more volume.

Standard Life < 8%

Octopus Investments > 4%

Skinny
Now u have your volume, looks like house broker has taken up the offering.
Standard dropping 500k may well be taking a profit on recent 72p purchase. They last bought at 95p,. I did read/hear somewhere that they have a limit on the amount that they will hold in any one company. Notice Octopus purchase dated last Friday so that cannot be the 72 placing as that is not yet confirmed until after the vote

nice couple of days, but must go through 95 which seems current resistance.
We might have to wait for next months results

Notice of Preliminary Results


Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, will announce its preliminary results for the year ended 31 December 2011 on Wednesday 7 March 2012.

A briefing for analysts will be held at 10.30am on the day of the results at the offices of Investec Bank plc, 2 Gresham Street, London EC2V 7QP.

Final Results.

Financial Highlights:

• Revenue up 8% to £34.4 million (2010: £31.9 million) at actual currency and 9% at constant currency¹

• Operating margin (pre-exceptional items²) up 190 basis points to 18.6% (2010: 16.7%)

○ Operating margin (post-exceptional items²) down 20 basis points to 13.4% (2010: 13.6%)

• Operating profit (pre-exceptional items²) up 20% to £6.4 million (2010: £5.3 million)

• Operating profit (post-exceptional items²) up 6% to £4.6 million (2010: £4.3 million)

• Basic earnings per share (pre-exceptional items²) up 11% to 4.26p (2010: 3.83p)

• Basic earnings per share (post-exceptional items²) decreased 2% to 3.10p (2010: 3.17p)

• Cash inflow from operating activities (pre-exceptional items²) of £5.5 million (2010: £8.1 million)

• Cash inflow from operating activities (post-exceptional items²) of £4.9 million (2010: £7.1 million)

• Following the acquisition of RESORBA, net debt³ was £13.4 million at 31 December 2011 (2010: net funds £3.9 million)

• Proposed final dividend of 0.305p per share, making a total dividend for the year of 0.45p per share (2010: 0.38p), an increase of 18%

Business Highlights:

• Foam revenues up 49%, driven by successful new product developments and including a customer product launch

• Foam revenues up 49%, driven by successful new product developments and including a customer product launch

• Silver alginate revenues up 5% excluding de-stocking by a major partner (down 2% including de-stocking)

• LiquiBand® revenues in Europe and the UK up 13%, maintaining our significant market positions in these geographies

• End-user sales of LiquiBand® US have increased over threefold in 2011 compared with 2010

• Successful €63.8 million acquisition in December of RESORBA, a German woundcare and wound closure business, financed by new debt and equity

• New Winsford site delivers efficiency and margin gains in its first year

TANKS - i don't know this company at all, but clearly they have pooed in their nest very badly, and on that basis alone i would not be at all tempted

Cynic
Cannot see where the drop has come from other than 1)longs at 72 wanting out with mm not giving support
2 the annual shorting , again with noq resistance from the mm
No real volume and no notice from major holders.
At recent results there were no surprises but some were expecting more.
There is a meeting of company and analysts soon

no idea ... only even looked because tanks asked me to and to comment

Annual General Meeting and Update on Trading

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, will hold its Annual General Meeting at 11.00 today.

Dr. Don Evans, Non-Executive Chairman of the Group, will make the following statement regarding current trading.

"I am pleased to report that the good start to the year, as highlighted in the 2011 Preliminary Results announcement on 7 March 2012, is continuing.

We continue to make good progress in the US market with our LiquiBand® range of products, with end-user sales increasing and further market share gains. We expect to see the impact of this progress in our ex-factory sales during the second half and we anticipate good growth for the full year. In relation to LiquiBand Flex®, we are well advanced with signing up and training distributors and are currently going through key evaluations which should be finalised by the end of the summer.

Our integration of RESORBA® is progressing to plan. We are advancing through the programme set out at the beginning of the year and we have now completed the first NHS tender for RESORBA®'s range of products, in line with our stated strategy. We expect the outcome of this first tender toward the end of the year. As a consequence of the RESORBA® acquisition, more of our Group revenues are now Euro denominated. The Group has hedged to protect profitability and, although underlying sales remain healthy, the consequent weakening of the currency could affect our headline revenue number on translation into sterling.

Elsewhere in the Group, our ActivHeal® range continues to perform well and the de-stocking effect that we experienced with one of our partners for silver alginate is now behind us. In our foam business, the targeted H2 launch of trilaminate foam dressings remains on track. However, as discussed in our Preliminary Results, 2012 foam revenues are expected to be impacted by the non-repetition of a large, roll-stock launch order in 2011, combined with our continuing strategy of focusing on higher margin business.

The effect of the expected reduction in foam revenues, together with the likely Euro impact, is that we anticipate full year Group revenues will be below expectations but with a negligible effect on profitability.

In conclusion, whilst global economic conditions remain challenging, the Board is pleased to confirm that we expect profitability for the full year 2012 to be in line with current market forecasts. The long term prospects for the Group remain excellent and we look forward to the coming months with confidence."

- ends -